Suggestions
Claudine van der Sande
Vice President, Head of CHI Program
Claudine van der Sande is a seasoned marketing professional with over a decade of experience in the field.
She has a strong background in digital marketing, content creation, and social media management.
Claudine excels in developing and implementing strategic marketing campaigns that drive brand awareness and engagement.
She is known for her creative approach to marketing strategies and her ability to analyze data to optimize campaign performance.
With a passion for storytelling, Claudine has successfully leveraged narratives to connect with audiences and drive results.
Her expertise spans across various industries, including technology, fashion, and hospitality.
Claudine is also proficient in market research, trend analysis, and competitor benchmarking, allowing her to stay ahead of industry trends.
She is a collaborative team player who thrives in fast-paced environments and is always eager to learn and implement new marketing techniques.
Claudine holds a Bachelor's degree in Marketing from a reputable university and regularly attends industry conferences to expand her knowledge and network.
In her free time, she enjoys volunteering for marketing-related causes and mentoring young professionals in the field.
Highlights
I am excited to present the company Xinvento B.V.. The purpose of Xinvento is to develop the future treatment of congenital hyperinsulinism.
For those who don't know my personal story, back in 2020, not long after my son was born, he was diagnosed with congenital hyperinsulinism (CHI).
CHI is a rare disease, and as a result, there is a lack of real treatment options.
Although my son is making good progress, I want to ensure he has access to modern medicine and the best medical treatment available to combat his condition.
With my background in the pharmaceutical industry, I felt compelled to use this experience to find a better treatment solution for my son and the countless lives around the world adversely impacted by congenital hyperinsulinism.
Our journey at Xinvento has started, and we have launched our website www.xinvento.com, so do check it out and learn more about the disease, the founding team (Piet Wigerinck and Sarah Hafith) and our mission.
I look forward to keeping you all updated on this rewarding adventure.
Thank you for your interest and support.
#impact #improvingqualityoflife #biotech #pharma #raredisease
